This free webinar is hosted by the Canadian Childhood Cannabinoid Clinical Trials (C4T), MedCan Support and Drug Science. Questions can be submitted beforehand to C4T.Canada@gmail.com or through twitter #C4TMedCanDrugScience22. This 90-minute panel discussion will include expert speakers including researchers, clinicians, and parents from Canada and Europe.
Matt Hughes is the Co-Founder and Director of MedCan Support, a hub for education, advocacy, research and support in the use of prescribed cannabis in paediatrics. Matt has been involved in the UK Medical Cannabis sector since early 2019 when his son Charlie was prescribed cannabis in the treatment of his severe treatment resistant epilepsy. Charlie has seen a dramatic reduction in seizures and much improved quality of life. Matt continues to campaign and advocate for population wide NHS access for children suffering with severe epilepsy and be a voice for patients and families within the growing private cannabis sector joining the executive committee of the UK Cannabis Industry Council.
Dr. Callie Seaman is a Plant Scientist and Formulation Chemist with over 20 years of experience in the hydroponic industry. She has worked with a number of licensed cannabis producers within the UK and internationally as a director and researcher helping to optimize and set up research programs around secondary metabolite production within cannabis. She first completed a degree in biomedical sciences, during which she worked for GlaxoSmithKline within the drug metabolism and pharmacokinetics department. She then went on to complete a PhD in fertilizer chemistry at Sheffield Hallam University whilst setting up a liquid fertilizer manufacturing company, formulating and taking to market a full range of products. As a patient she is passionate about educating everyone about cannabis and helping to support patients through their journey with cannabis prescription, through volunteering for organization such as MedCan Support and PLEA (Patient-Led Engagement for Access).
Dr. Anne Katrin Schlag is a Chartered Psychologist and Head of Research at Drug Science. She leads the research for the Drug Science Medical Cannabis Working Group, focusing on controversies surrounding medical cannabis, the improvement of patient access, and the continued development of education and stakeholder communication about medical cannabis. Dr. Schlag is currently working on progressing the scientific evidence base of medical cannabis to include Patient Reported Outcomes, observational studies (such as T21) and the application of Multi-Criteria Decision Analysis to assess the benefits and safety of medical cannabis. She holds Honorary Fellowships at both Imperial College London and King’s College London, chairs the research subgroup of the Cannabis Industry Council, and is scientific advisor to the Primary Care Cannabis Network.
Dr. Bruce Crooks is an Associate Professor of pediatric hematologist/oncologist at IWK Health and Dalhousie University in Halifax, Nova Scotia. Originally from, and trained in the UK, he has been in Halifax since 2002, caring predominantly for children with cancer, particularly CNS tumours, patients requiring bone marrow transplant, retinoblastoma, and solid tumours. His interest in medical cannabis grew from the interest families had in using it for supportive and curative care, despite the paucity of medical information available. He is interested in helping to determine the place of medical cannabis in the treatment of children, not only with cancers but also with other medical conditions, and facilitating frank and open dialogue between families and healthcare professionals about medical cannabis.
Alexander Repetski is a Media Production Artist and Communications Strategist. His interest in medical cannabis became increasingly important in 2012 when his daughter Gwenevere was diagnosed with intractable epilepsy. He came across cannabis while researching various areas of neuroscience in an effort to understand treatment options. After repeated failures of traditional therapies, he has successfully managed Gwenevere’s seizures with specialized cannabis cultivars, extractions and formulations. He is regularly asked to speak about his experiences to audiences both within the cannabis patient community and the academic world. He has worked in the cannabis industry with data start-ups and LP’s for the past 7 years. Alexander is now focused on assisting research of all forms to advance the evidence-based understanding of cannabis treatment. He enjoys fresh ideas and hugs from his children.
Dr. Lauren Kelly is a Pharmacologist, Assistant Professor in the Department of Pharmacology and Therapeutics, and the Department of Community Health Sciences at the University of Manitoba. She is a Certified Clinical Research Professional and a Systematic Reviewer. Dr. Kelly received her Doctorate in Pharmacology and Toxicology from the University of Western Ontario and completed two post-doctoral fellowships at the Hospital for Sick Children and Mount Sinai Hospital in Toronto. Dr. Kelly is the PI for the Clinical Pharmacology Lab, the Clinical Trials Director and a Scientist at the Children’s Hospital Research Institute of Manitoba, and the Scientific Director of C4T.
For more information on C4T, MedCan Support or Drug Science please visit the websites below.
MedCan Support: https://medcansupport.co.uk/
Drug Science: https://drugscience.org.uk/
This event will be broadcast with closed captions on YouTube Live by the University of Manitoba. A recording will be available and sent to everyone who has registered after the webinar.